Anavex updates regulatory strategy for blarcamesine
Anavex Life Sciences has withdrawn its application for marketing authorization for Blarcamesine in the European Union and will gather additional information while continuing dialogue with the European Medicines Agency to resolve the issues raised by the Committee for Medicinal Products…












